At a glance
ClinicalIndex Comparison RecordN/ACompleted· 30 enrolled
Drug / intervention
Accell Evo3 Prospective Usedevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy and Safety of Integra Accell Evo3 Demineralized Bone Matrix in Instrumented Lumbar Spine Fusion
In Brief
A clinical study evaluating Accell Evo3 Prospective Use for Stenosis and 2 related conditions. Completed, enrolled 30 participants across 1 site.
Detailed Summary
The objective of this study is to prospectively evaluate the performance of Integra Accell Evo3 Demineralized Bone Matrix as an adjunct for instrumented lumbar spine fusion with a retrospective comparison to a historical patient cohort.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsStenosis, Spondylosis, Degenerative Changes
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartAug 2012
First PostedOct 2012
Primary CompletionJul 2016
Study CompletionOct 2016
TodayJul 2026
First PostedOct 26, 2012
Enrollment StartAug 1, 2012
Primary CompletionJul 1, 2016
Study CompletionOct 1, 2016
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 13.7 years ago
Interventions
Accell Evo3 Prospective Usedevice